Literature DB >> 26825709

HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Roberta Valsecchi1, Nadia Coltella2, Daniela Belloni2, Manfredi Ponente2, Elisa Ten Hacken2, Cristina Scielzo2, Lydia Scarfò2, Maria Teresa Sabrina Bertilaccio2, Paola Brambilla3, Elisa Lenti2, Filippo Martinelli Boneschi3, Andrea Brendolan2, Elisabetta Ferrero2, Marina Ferrarini2, Paolo Ghia4, Giovanni Tonon2, Maurilio Ponzoni5, Federico Caligaris-Cappio4, Rosa Bernardi2.   

Abstract

Hypoxia-inducible transcription factors (HIFs) regulate a wide array of adaptive responses to hypoxia and are often activated in solid tumors and hematologic malignancies due to intratumoral hypoxia and emerging new layers of regulation. We found that in chronic lymphocytic leukemia (CLL), HIF-1α is a novel regulator of the interaction of CLL cells with protective leukemia microenvironments and, in turn, is regulated by this interaction in a positive feedback loop that promotes leukemia survival and propagation. Through unbiased microarray analysis, we found that in CLL cells, HIF-1α regulates the expression of important chemokine receptors and cell adhesion molecules that control the interaction of leukemic cells with bone marrow and spleen microenvironments. Inactivation of HIF-1α impairs chemotaxis and cell adhesion to stroma, reduces bone marrow and spleen colonization in xenograft and allograft CLL mouse models, and prolongs survival in mice. Of interest, we found that in CLL cells, HIF-1α is transcriptionally regulated after coculture with stromal cells. Furthermore, HIF-1α messenger RNA levels vary significantly within CLL patients and correlate with the expression of HIF-1α target genes, including CXCR4, thus further emphasizing the relevance of HIF-1α expression to CLL pathogenesis.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26825709      PMCID: PMC4946537          DOI: 10.1182/blood-2015-07-657056

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place.

Authors:  B Herreros; S M Rodríguez-Pinilla; R Pajares; M A Martínez-Gónzalez; R Ramos; I Munoz; S Montes-Moreno; M Lozano; L Sánchez-Verde; G Roncador; M Sánchez-Beato; R D de Otazu; M Pérez-Guillermo; M J Mestre; C Bellas; M A Piris
Journal:  Leukemia       Date:  2010-01-14       Impact factor: 11.528

Review 2.  Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

Authors:  John C Byrd; Jeffrey J Jones; Jennifer A Woyach; Amy J Johnson; Joseph M Flynn
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Authors:  Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

Review 5.  Regulation of CLL survival by hypoxia-inducible factor and its target genes.

Authors:  Idit Shachar; Sivan Cohen; Ayelet Marom; Shirly Becker-Herman
Journal:  FEBS Lett       Date:  2012-07-24       Impact factor: 4.124

6.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21

Review 7.  B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens.

Authors:  Nicholas Chiorazzi; Katerina Hatzi; Emilia Albesiano
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

8.  Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.

Authors:  Puja Sapra; Patricia Kraft; Mary Mehlig; Jennifer Malaby; Hong Zhao; Lee M Greenberger; Ivan D Horak
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

9.  Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

Authors:  Puja Sapra; Patricia Kraft; Fabio Pastorino; Domenico Ribatti; Melissa Dumble; Mary Mehlig; Maoliang Wang; Mirco Ponzoni; Lee M Greenberger; Ivan D Horak
Journal:  Angiogenesis       Date:  2011-03-31       Impact factor: 9.596

10.  HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse.

Authors:  Nadia Coltella; Stefano Percio; Roberta Valsecchi; Roberto Cuttano; Jlenia Guarnerio; Maurilio Ponzoni; Pier Paolo Pandolfi; Giovanni Melillo; Linda Pattini; Rosa Bernardi
Journal:  EMBO Mol Med       Date:  2014-05       Impact factor: 12.137

View more
  28 in total

1.  HIF-1α: a potential treatment target in chronic lymphocytic leukemia.

Authors:  Martina Seiffert
Journal:  Haematologica       Date:  2020-04       Impact factor: 9.941

Review 2.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

3.  Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.

Authors:  Sara Serra; Tiziana Vaisitti; Valentina Audrito; Cinzia Bologna; Roberta Buonincontri; Shih-Shih Chen; Francesca Arruga; Davide Brusa; Marta Coscia; Ozren Jaksic; Giorgio Inghirami; Davide Rossi; Richard R Furman; Simon C Robson; Gianluca Gaidano; Nicholas Chiorazzi; Silvia Deaglio
Journal:  Blood Adv       Date:  2016-11-22

Review 4.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

5.  Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.

Authors:  Han Zhang; Zheng Chen; Roberto N Miranda; L Jeffrey Medeiros; Nami McCarty
Journal:  Blood       Date:  2017-06-07       Impact factor: 22.113

6.  Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.

Authors:  Z Wu; R Chen; L Wu; L Zou; F Ding; M Wang; X Liu
Journal:  Clin Transl Oncol       Date:  2017-06-06       Impact factor: 3.405

7.  HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia.

Authors:  Wancheng Guo; Daomiao Liang; Peilong Wang; Le Yin; Huifang Zhang; Cheng Xing; Zineng Huang; Yinghua Wu; Heng Li; Zhao Cheng; Xiaojuan Xiao; Jing Liu; Zhihua Wang; Hongling Peng
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-10

8.  Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4.

Authors:  Ping-Ting Gao; Guang-Yu Ding; Xuan Yang; Rui-Zhao Dong; Bo Hu; Xiao-Dong Zhu; Jia-Bin Cai; Yuan Ji; Guo-Ming Shi; Ying-Hao Shen; Jian Zhou; Jia Fan; Hui-Chuan Sun; Cheng Huang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

9.  Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.

Authors:  Bryce A Manso; Henan Zhang; Molly G Mikkelson; Kimberly A Gwin; Charla R Secreto; Wei Ding; Sameer A Parikh; Neil E Kay; Kay L Medina
Journal:  Leukemia       Date:  2018-10-05       Impact factor: 11.528

Review 10.  Dynamic responses of the haematopoietic stem cell niche to diverse stresses.

Authors:  Antoniana Batsivari; Myriam Luydmila Rachelle Haltalli; Diana Passaro; Constandina Pospori; Cristina Lo Celso; Dominique Bonnet
Journal:  Nat Cell Biol       Date:  2020-01-06       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.